Use of HIV Resistance Testing After Prolonged Treatment Interruption

Background:HIV-1 genotypic resistance testing is not routinely recommended for patients who have been off antiretroviral therapy (ART) for longer than 4 weeks. We assessed the results and use of resistance testing in patients off ART. Methods:All HIV resistance genotypes from November 2003 through April 2008 were reviewed from one large teaching hospital and two private HIV practices. Inclusion criterion was having a genotypic resistance test after an ART interruption of at least 2 months. Medical records were reviewed using a standardized data collection sheet. Results:Sixty-two of 304 treatment-experienced patients with HIV genotypes met the inclusion criteria. Prior cumulative ART class exposure included nucleoside reverse transcriptase inhibitors in 54 patients, nonnucleoside reverse transcriptase inhibitors in 32 patients, and protease inhibitors in 30 patients. Resistance testing was performed at a mean of 12 months (range, 2.5-48 months) after ART interruption. The mean time between ART interruption and resistance testing did not differ for patients with mutations and those without mutations detected. Seventeen of 62 (27.4%) patients were found to have resistance mutations. Eleven patients were found to have mutations to nonnucleoside reverse transcriptase inhibitors, four patients had mutations to nucleoside reverse transcriptase inhibitors, and two patients had protease inhibitor-associated mutations. No patient had multiclass resistance. Among the 17 patients with mutations after treatment interruption, 15 had mutations that were either not present on a prior genotype (n = 2) or did not have a prior genotype (n = 13). Conclusions:HIV genotypic resistance assays may identify mutations even when performed after a prolonged treatment interruption and may offer clinically significant information. Current guidelines that discourage resistance testing after treatment interruptions of longer than 4 weeks should be re-evaluated.

[1]  D. Celentano,et al.  Nonstructured Treatment Interruptions Among Injection Drug Users in Baltimore, MD , 2009, Journal of acquired immune deficiency syndromes.

[2]  D. Richman,et al.  2022 update of the drug resistance mutations in HIV-1. , 2022, Topics in antiviral medicine.

[3]  S. Hammer,et al.  Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[4]  D. Richman,et al.  Persistence of Transmitted Drug Resistance among Subjects with Primary Human Immunodeficiency Virus Infection , 2008, Journal of Virology.

[5]  A. Mocroft,et al.  Interruption of combination antiretroviral therapy and risk of clinical disease progression to AIDS or death , 2007, HIV medicine.

[6]  Joseph Quinn,et al.  An updated systematic overview of triple combination therapy in antiretroviral-naive HIV-infected adults , 2006, AIDS.

[7]  N. Pantazis,et al.  Highly Active Antiretroviral Therapy Interruption: Predictors and Virological and Immunologic Consequences , 2006, Journal of acquired immune deficiency syndromes.

[8]  Sarah Palmer,et al.  Selection and persistence of non-nucleoside reverse transcriptase inhibitor-resistant HIV-1 in patients starting and stopping non-nucleoside therapy , 2006, AIDS.

[9]  D. Pillay,et al.  Determinants of HIV drug resistance mutations in plasma virus after treatment interruption , 2005, AIDS.

[10]  Rebecca Hoh,et al.  Interruption of treatment with individual therapeutic drug classes in adults with multidrug-resistant HIV-1 infection. , 2005, The Journal of infectious diseases.

[11]  J. García-Lerma Diversity of thymidine analogue resistance genotypes among newly diagnosed HIV-1-infected persons. , 2005, The Journal of antimicrobial chemotherapy.

[12]  J. Strathern,et al.  Sensitive drug-resistance assays reveal long-term persistence of HIV-1 variants with the K103N nevirapine (NVP) resistance mutation in some women and infants after the administration of single-dose NVP: HIVNET 012. , 2005, The Journal of infectious diseases.

[13]  Richard D Moore,et al.  An Improvement in Virologic Response to Highly Active Antiretroviral Therapy in Clinical Practice From 1996 Through 2002 , 2005, Journal of acquired immune deficiency syndromes.

[14]  M. Segal,et al.  Persistence of primary drug resistance among recently HIV-1 infected adults , 2004, AIDS.

[15]  V. Calvez,et al.  Comparison of the Dynamics of Resistance-Associated Mutations to Nucleoside Reverse Transcriptase Inhibitors, Nonnucleoside Reverse Transcriptase Inhibitors, and Protease Inhibitors after Cessation of Antiretroviral Combination Therapy , 2004, Antimicrobial Agents and Chemotherapy.

[16]  Gary Collins,et al.  Structured treatment interruption in patients with multidrug-resistant human immunodeficiency virus. , 2003, The New England journal of medicine.

[17]  A. Sönnerborg,et al.  Kinetics of HIV-1 RNA and resistance-associated mutations after cessation of antiretroviral combination therapy , 2001, AIDS.

[18]  R Hoh,et al.  Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. , 2001, The New England journal of medicine.

[19]  M. Youle,et al.  Rapid decline in detectability of HIV-1 drug resistance mutations after stopping therapy. , 1999, AIDS.

[20]  C. Verhofstede,et al.  Interruption of reverse transcriptase inhibitors or a switch from reverse transcriptase to protease inhibitors resulted in a fast reappearance of virus strains with a reverse transcriptase inhibitor-sensitive genotype. , 1999, AIDS.

[21]  M. Uhlén,et al.  Persistence of azidothymidine-resistant human immunodeficiency virus type 1 RNA genotypes in posttreatment sera , 1992, Journal of Virology.

[22]  S. Hammer,et al.  Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel. , 2000, Topics in HIV medicine : a publication of the International AIDS Society, USA.